Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 24Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 5Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 2Urothelial Cancer 1

Interventions

Surveys and Questionnaires 9Cystectomy 6Blood Specimen Collection 5Neoadjuvant Therapy 4Cystoscopy 4Drug Therapy 3avelumab 2Urination 2Urinary Diversion 2Surgical Procedures, Operative 2Radiotherapy 2Pioglitazone 2Microarray Analysis 2Methods 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Immunohistochemistry 2Defecation 2Biopsy 25-aminolevulinic acid hexyl ester 2trastuzumab deruxtecan 1sargramostim 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Watchful Waiting 1Urinary Sediment Analysis 1Therapeutics 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Urinary Bladder Neoplasms × avelumab × Clear all
NCT04822350 2026-04-02

AVENANCE

Pfizer

Completed
596 enrolled 43 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05568407 2023-07-13

A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Pfizer

Terminated
19 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡